WZH-17-002
Product Specifications
Target
PROTACs, Akt, ERK, ALK
Related Pathways
Cytoskeletal Signaling, PI3K/Akt/mTOR signaling, Angiogenesis, MAPK, Tyrosine Kinase/Adaptors, PROTAC
Bioactivity
WZH-17-002 is an ALKPROTAC degrader based on WZH-15-125, with a DC50 of 25 nM. This compound enhances the efficacy against ALK mutations that confer resistance to Lorlatinib. Moreover, WZH-17-002 significantly reduces resistance in ALK fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196M xenograft mouse models.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog